Full Fed. Circ. To Review On-Sale Bar In Angiomax Patent Suit

Law360, New York (November 13, 2015, 7:40 PM EST) -- The full Federal Circuit on Friday agreed to review a panel decision overruling a trial judge and invalidating two of The Medicines Co.'s patents for the blood-thinning drug Angiomax, positioning the court to consider questions about what constitutes an on-sale bar.

In a brief order, the appeals court vacated the three-judge panel's July decision, which found the patents were invalid because the claimed process was offered for sale well before the patent applications were filed.

Under the so-called on-sale bar, an invention cannot be patented if it was ready for patenting and was subject to a commercial offer for sale more...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!